Get the Stockscreener App
72.51
0.33%
-0.24
Pre-market:
73.49
0.98
+1.35%
Insmed Inc stock is traded at $72.51, with a volume of 1.66M.
It is down -0.33% in the last 24 hours and down -1.81% over the past month.
Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.
See More
Previous Close:
$72.75
Open:
$73.5
24h Volume:
1.66M
Relative Volume:
1.05
Market Cap:
$12.97B
Revenue:
$342.96M
Net Income/Loss:
$-864.29M
P/E Ratio:
-13.06
EPS:
-5.55
Net Cash Flow:
$-636.03M
1W Performance:
+11.13%
1M Performance:
-1.81%
6M Performance:
-4.01%
1Y Performance:
+151.68%
1-Day Range:
$71.50
$73.62
1-Week Range:
$63.73
$73.62
52-Week Range:
$21.92
$80.53
Insmed Inc Stock (INSM) Company Profile
Name
Insmed Inc
Sector
Industry
Phone
908-977-9900
Address
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
Compare INSM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
72.51 | 12.97B | 342.96M | -864.29M | -636.03M | -5.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-23-24 | Initiated | Truist | Buy |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Jul-26-23 | Initiated | Guggenheim | Buy |
| Dec-09-22 | Initiated | Mizuho | Buy |
| Dec-07-22 | Initiated | Barclays | Overweight |
| Nov-18-22 | Initiated | BofA Securities | Buy |
| Apr-27-22 | Initiated | Goldman | Buy |
| Dec-06-21 | Initiated | JP Morgan | Overweight |
| Oct-19-21 | Resumed | Monness Crespi & Hardt | Buy |
| Oct-19-21 | Resumed | Morgan Stanley | Overweight |
| Oct-08-21 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Oct-12-20 | Resumed | Stifel | Buy |
| Sep-03-19 | Initiated | Goldman | Buy |
| Apr-09-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-15-19 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Jan-17-19 | Upgrade | Goldman | Neutral → Buy |
| Jan-02-19 | Initiated | Canaccord Genuity | Buy |
| Aug-06-18 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jul-23-18 | Initiated | Goldman | Neutral |
| Apr-23-18 | Upgrade | Credit Suisse | Neutral → Outperform |
| Mar-21-18 | Initiated | Morgan Stanley | Overweight |
| Jan-18-18 | Initiated | Credit Suisse | Neutral |
| Sep-05-17 | Reiterated | Evercore ISI | Outperform |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Jul-11-17 | Initiated | Robert W. Baird | Outperform |
| Mar-15-16 | Initiated | Stifel | Buy |
| Nov-09-15 | Downgrade | UBS | Buy → Neutral |
| Oct-06-15 | Reiterated | H.C. Wainwright | Buy |
| Jun-09-15 | Initiated | Citigroup | Neutral |
| Mar-26-14 | Reiterated | HC Wainwright | Buy |
View All
Insmed Inc Stock (INSM) Latest News
The five-year returns have been solid for Insmed (NASDAQ:INSM) shareholders despite underlying losses increasing - Yahoo Finance UK
Insmed CEO William Lewis sells shares worth $2.71 million - MSN
Insmed Incorporated (NASDAQ:INSM) Short Interest Up 18.7% in December - MarketBeat
Is Insmed (NASDAQ:INSM) Using Debt Sensibly? - Simply Wall St
Insmed chief medical officer sells $95,108 in stock - MSN
Is Insmed Incorporated (INSM) One of the Best Russell 2000 Stocks to Invest in According to Analysts? - Yahoo Finance
Insmed (FRA:IM8N) Shares Outstanding (EOP) : 178.8 Mil (As of Sep. 2024) - GuruFocus.com
Insmed's chief people strategy officer sells $59,923 in stock - MSN
Goldman Sachs Sees High Merger Odds For This Large-Cap Biopharma In Trump 2.0 Era: Retail Has Been Alert - MSN
Insmed Incorporated (NASDAQ:INSM) Insider Sells $95,108.48 in Stock - MarketBeat
Insmed Incorporated (NASDAQ:INSM) CEO William Lewis Sells 31,805 Shares of Stock - MarketBeat
Insmed COO Roger Adsett sells $100,125 in stock - MSN
Hennion & Walsh Asset Management Inc. Sells 43,522 Shares of Insmed Incorporated (NASDAQ:INSM) - MarketBeat
Insmed chief medical officer sells $95,108 in stock By Investing.com - Investing.com Australia
Assenagon Asset Management S.A. Has $36.26 Million Position in Insmed Incorporated (NASDAQ:INSM) - MarketBeat
Insider Sell: Roger Adsett Sells 1,457 Shares of Insmed Inc (INS - GuruFocus.com
Insider Sell: Schaeffer Orlov S Nicole Sells Shares of Insmed In - GuruFocus.com
Insmed's chief people strategy officer sells $59,923 in stock By Investing.com - Investing.com Australia
Insmed COO Roger Adsett sells $100,125 in stock By Investing.com - Investing.com South Africa
Insmed CEO William Lewis sells shares worth $2.71 million By Investing.com - Investing.com Canada
Why INSM Stock Is Advancing Today - MSN
Insmed’s gene therapy poised to challenge DMD landscape after IND clearance - Yahoo Finance
Evolving Landscape of Cardiology Segment: Key Market Insights of Latest Published Rare Cardiovascular Diseases Report — Giant-Cell Arteritis, Pulmonary Arterial Hypertension, and Restrictive Cardiomyopathy | DelveInsight - GlobeNewswire Inc.
Capital CS Group LLC Buys New Stake in Insmed Incorporated (NASDAQ:INSM) - MarketBeat
Insmed (NASDAQ:INSM) Stock Price Up 6%Should You Buy? - MarketBeat
How Is The Market Feeling About Insmed? - Benzinga
Insmed issues preliminary revenue results, guidance for Arikayce - MSN
Insmed COO Roger Adsett sells $368,472 in stock By Investing.com - Investing.com Nigeria
Insmed chief commercial officer sells shares worth $659,800 By Investing.com - Investing.com Australia
Insmed chief legal officer sells $242,815 in common stock By Investing.com - Investing.com Australia
Insmed’s chief medical officer sells $725,820 in stock By Investing.com - Investing.com Nigeria
Insmed's chief medical officer sells $725,820 in stock By Investing.com - Investing.com Australia
Insmed CFO Sara Bonstein sells $392,601 in stock By Investing.com - Investing.com Australia
Insmed Incorporated (NASDAQ:INSM) Stock Holdings Boosted by Harbor Capital Advisors Inc. - MarketBeat
Insmed's chief medical officer sells $725,820 in stock - Investing.com India
Insmed CFO Sara Bonstein sells $392,601 in stock - Investing.com India
Insmed Incorporated (NASDAQ:INSM) CFO Sells $67,925.52 in Stock - MarketBeat
Insmed CEO William Lewis sells $995,012 in stock By Investing.com - Investing.com South Africa
Insmed CEO William Lewis sells $995,012 in stock - Investing.com India
Insmed chief people strategy officer sells shares worth $312,259 By Investing.com - Investing.com Canada
Insmed Inc Stock (INSM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Insmed Inc Stock (INSM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Adsett Roger | Chief Operating Officer |
Jan 14 '25 |
Sale |
68.72 |
1,457 |
100,125 |
146,082 |
| Schaeffer Orlov S Nicole | Chief People Strategy Officer |
Jan 14 '25 |
Sale |
68.72 |
872 |
59,924 |
97,083 |
| Lewis William | Chair and CEO |
Jan 15 '25 |
Option Exercise |
22.76 |
18,750 |
426,750 |
411,339 |
| Lewis William | Chair and CEO |
Jan 15 '25 |
Option Exercise |
10.85 |
6,830 |
74,106 |
240,754 |
| Lewis William | Chair and CEO |
Jan 15 '25 |
Sale |
70.18 |
31,805 |
2,232,161 |
379,534 |
| Lewis William | Chair and CEO |
Jan 15 '25 |
Sale |
70.17 |
6,830 |
479,295 |
233,924 |
0.65%
4.62%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):